Contineum Therapeutics, Inc.
CTNM$102M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO41 employees
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 4, 2026
6wMarket Overview
Stock performance and key metrics
CTNM News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
PIPE-791 Dose A
Idiopathic Pulmonary Fibrosis
PIPE-505
Sensorineural Hearing Loss
PIPE-307 Dose A
Relapsing Remitting Multiple Sclerosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PIPE-791 Dose A | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
PIPE-505 | Phase 2 | Sensorineural Hearing Loss | - | - |
PIPE-307 Dose A | Phase 2 | Relapsing Remitting Multiple Sclerosis | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply